Clearmind Medicine Announces Publication of U.S. Patent Application for MDMA-Based PTSD Treatment

Filing content

Clearmind Medicine announced the publication of a U.S. patent application for its MDMA and N-acylethanolamines combination therapy for PTSD, developed in collaboration with NeuroThera Labs. The publication strengthens the company's IP portfolio amid new FDA guidance on psychedelic drug development.